Media Release
Early, intensive management of diabetes is essential to reduce the risk of diabetic complications.
Despite this, fewer than 10% of Australians with diabetes are adequately treated and complication free.
Glucagon-like peptide-1 receptor agonists are a group of medicines that provide robust glycaemic control and weight loss benefits. This makes them an ideal choice for intensifying treatment in many people with type 2 diabetes.
Guild Learning and Development has partnered with Novo Nordisk in the development of a new online module titled Ozempic® (semaglutide) – a once-weekly GLP-1 for the management of type 2 diabetes.
The module looks at the importance of early intensification of diabetes management, and provides information on the dosing, administration and clinical use of Ozempic®.
This activity has been accredited for 1.5 hours of Group 1 CPD (or 1.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan, which can be converted to 1.5 hours of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
To enrol in this course, visit: guilded.guild.org.au.
Please contact Guild Learning and Development on 1800 049 056 or email learninganddevelopment@guild.org.au for more information.
Guild Learning and Development thanks Novo Nordisk for its financial support and assistance in the development of this course.
Text by: The Pharmacy Guild of Australia
